to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia (SIPHON)

JW Pharmaceutical

Status and phase

Completed

Phase 4

Conditions

HbA1c Level Associated With Lipid Compositions

Treatments

Drug: Pitavastatin calcium 4mg

Drug: Pitavastatin calcium 2mg

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02056847

JW-PTV-713

Details and patient eligibility

About

Primary Objective

: To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG).

H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4

µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)

Full description

Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group: Pitavastatin calcium (LIVALO) 2mg tab

Study Site: Multi-centers in Korea

Period: For 24months after IRB approval at each site (Including 12months of subject enrollment period)

Efficacy End points

A. Primary end point The change of HbA1c before and after taking LIVALO

B. Secondary end point

Incidence of diabetes within 1year after registration (based; FPG ≥126mg/dL or to need taking diabetes medication)
Incidence of major cardiovascular (TLR-MACE) events within 1 year after registration
Incidence of total cardiovascular (TVR-MACE) events within 1 year after registration
The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)
The changes of hs-CRP
The changes of Adiponectin
The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]

Statistical Methods

Efficacy A. Primary efficacy endpoint analysis Describe statistics of basic about the HbA1c variation before and after taking LIVALO by groups. In order to verify noninferiority of test drug, check that upper limit of confidence interval of the one-sided 97.5% is less than 0.4% about difference of HbA1c variation between the control group and the test group, before and after taking LIVALO.

B. Secondary efficacy endpoint analysis Continuous variables

:Present the mean, standard deviation, minimum, and maximum values for TC, TG, LDL-C, HDL-C, Fasting serum insulin, Fasting plasma glucose and HOMA IR, HOMA β etc. by each visit and in each group. In comparison with intergroup, using two-sample t-test for normal distribution and using Wilcoxon rank sum test for non-normal distribution. Also In comparison with the same group, using paired t-test for normal distribution and using Wilcoxon signed rank test for non-normal distribution.

Discrete variables

: The number and percentage of the subjects for incidence of DM and cardiovascular event are described of each group and the ratio of the intergroup comparison use χ2-test or Fisher's exact test.
Safety All the AEs and the ADRs which manifested more than once are described by the frequency and percentage of each group and use χ2-test or Fisher's exact test for intergroup comparison about the rate of AEs and ADRs Laboratory tests and vital signs are analyzed descriptive statistics quantity of each group, and in comparison with intergroup, use two-sample t-test for normal distribution and use Wilcoxon rank sum test for non-normal distribution. Also, In comparison with the same group, use paired t-test for normal distribution and use Wilcoxon signed rank test for non-normal distribution.

Clinical laboratory test is analyzed the frequency and percentage of the outside normal range of subjects, and using χ2-test or Fisher's exact test with intergroup.

Enrollment

313 patients

Sex

All

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and Female patients who are more than 20 years old or 70 years old or less.
Patient who voluntarily sign on written informed consent form
Patient who LDL-C ≥ 100mg/dl or was diagnosed with hyperlipidemia
Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level ≥ 100mg/dL and < 126mg/dL when FPG measured twice.

Exclusion criteria

Patient who has familial hypercholesterolemia
Patient who has been diagnosed with Type1, Type2 DM or secondary DM(diabetes mellitus) at the screening visit (Diagnostic criteria of DM: HbA1c≥ 6.5%)
Patient who has received antidiabetic within 6weeks to the screening visit
Patient who has been taking insulin continuously or to be needed in the future
Patient who has a history of gastrectomy
Patient who is suspected or diagnosed with malignant tumor within last 10 years
Patient who has serious pancreatic disease or endocrine disorders
Patient who currently takes Cyclosporine
Patient who has a medical history of hypersensitivity to Pitavastatin calcium
Patient who has suspected renal failure (serum creatinine ≥2.0 mg/dL)
Patient who has suspected liver dysfunction (more than 2.5 times the upper limit of normal AST or ALT)
Patient who has more than 3 times the upper limit of normal CPK
Patient who is breastfeeding, pregnant or planning pregnancy
Patient who deemed inappropriate as subject in the opinion of the Principal Investigator or Investigator